A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

Inclusion Criteria:

   - Cytologically or histologically confirmed solid tumor that is inoperable locally
   advanced, metastatic, or recurrent.

   - Dose-escalation (single-agent and combination therapy): Subjects with a solid tumor
   that is unresectable or metastatic and for which life-prolonging therapies do not
   exist or available therapies are intolerable or no longer effective.

   - Expansion Cohort A (ccRCC): Subjects with previously treated advanced RCC with clear
   cell histology (including those with a sarcomatoid component) who have
   radiographically progressed following treatment with at least one prior systemic
   anticancer regimen for inoperable locally advanced or metastatic disease.

   - Expansion Cohorts B and E (nccRCC): Subjects with previously treated advanced RCC with
   non-clear cell histology who have radiographically progressed following treatment with
   at least one prior systemic anticancer regimen for inoperable locally advanced or
   metastatic disease.

   - Expansion Cohorts C and F (HR+ BC): Subjects with breast cancer that is hormone
   receptor positive (ER+ and/or PR+) and negative for human epidermal growth factor
   receptor 2 (HER-2) and who have radiographically progressed during or following
   treatment with at least one prior systemic anticancer regimen for inoperable locally
   advanced or metastatic disease.

   - Expansion Cohorts D and G (mCRPC): Subjects with metastatic CRPC (adenocarcinoma of
   the prostate). Neuroendocrine differentiation and other features permitted if
   adenocarcinoma is the primary histology.

   - Expansion Cohort H (CRC): Subjects with histologically confirmed unresectable, locally
   advanced, or metastatic adenocarcinoma of the colon or rectum, KRAS/NRAS wild-type
   (confirmed via local testing report) and determined NOT to have microsatellite
   instability high (MSI-high) or mismatch repair deficient (dMMR) by local testing, who
   received the following standard of care chemotherapy regimens as prior therapy for
   metastatic CRC:

      - Fluoropyrimidine, irinotecan and oxaliplatin, with or without an anti-VEGF
      monoclonal antibody (bevacizumab)

      - Anti-EGFR monoclonal antibody (cetuximab or panitumumab)

      - BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with
      BRAF V600E mutations

   - Expansion Cohorts: Subjects must have measurable disease per RECIST 1.1.

   - Tumor tissue material:

      - Subjects in the non-biomarker cohort provide archival, if available, or fresh
      tumor tissue if it can be safely obtained.

   - Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs),
   including immune-related adverse events (irAEs), related to any prior treatments,
   unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.

   - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.

   - Adequate organ and marrow function.

   - Sexually active fertile subjects and their partners must agree to use highly effective
   methods of contraception.

   - Female subjects of childbearing potential must not be pregnant at screening.

Exclusion Criteria:

   - Prior treatment with XL092 (all cohorts), prior treatment with PD-L1/PD-1 targeting
   immune checkpoint inhibitor (Cohorts E, F, G, and H only), or prior treatment with
   regorafenib and/or TAS-102 (Cohort H only).

   - Receipt of any type of small molecule kinase inhibitor within 2 weeks before first
   dose of study treatment.

   - Receipt of any type of anticancer antibody, systemic chemotherapy, or hormonal
   anticancer therapy within 4 weeks before first dose of study treatment.

   - Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy
   within 4 weeks before first dose of study treatment. Subjects with clinically relevant
   ongoing complications from prior radiation therapy are not eligible.

   - Known brain metastases or cranial epidural disease unless adequately treated with
   radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks
   before first dose of study treatment.

   - Uncontrolled, significant intercurrent or recent illness.

   - Concomitant use of certain medications.

   - Corrected QT interval calculated by the Fridericia formula (QTcF) > 450 ms for males
   and > 470 ms for females. Single ECGs are no longer permitted.

   - Pregnant or lactating females.

   - Diagnosis of another malignancy within 2 years before first dose of study treatment,
   except for superficial skin cancers, or localized, low grade tumors deemed cured and
   not treated with systemic therapy.

Additional Exclusion Criteria for XL092 + Atezolizumab Combination Therapy Cohorts ONLY:

   - Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
   form of immunosuppressive therapy within 2 weeks prior to first dose of study
   treatment.

   - Administration of a live, attenuated vaccine within 30 days before first dose of study
   treatment.

Additional Exclusion Criteria for XL092 + Avelumab Combination Therapy Cohorts ONLY:

   - Active autoimmune disease that might deteriorate when receiving an immunostimulatory
   agent.

   - Administration of a live, attenuated vaccine within 30 days before first dose of study
   treatment.